The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 220
- 试验地点
- 1
- 主要终点
- The Clinical Dementia Rating-Sum of Boxes (CDR-SB) change score
研究概览
简要总结
Background and objects Amyloid plaques and tau protein are the landmarks of neurodegeneration in Alzheimer's disease (AD). On the other hand, it is reported that cerebral ischemia may induce amyloid plaques and tau protein accumulation. However, it was difficult to in vivo disentangle the complex and dynamic interactions between AD pathophysiology and cerebral vascular injury during the post-stroke cognitive impairment development in the past. With the advent of novel radiotracers specific to cerebral amyloid plaques and tau protein, we aim to conduct a prospective multimodal neuroimaging cohort study to investigate the contribution of vascular injury, amyloid plaque and tau protein to cognitive impairment.
Subjects and methods The prospective project plans to recruit patients with vascular cognitive impairment (VCI) (Group A, n=80), Alzheimer's disease/mild cognitive impairment (MCI) (Group B, n = 120), fronto-temporal dementia (FTD) (Group C, n =30), and progressive supranuclear palsy (PSP) (Group E, n = 80). In addition, another 30 healthy people will be recruited as the control group (Group D, n=30). [18F]AV45 and [18F]MNI-958(PMPBB3) PET will be done for imaging cerebral amyloid plaque and tau protein distribution, brain MRI for obtaining structural and functional information, and neuropsychological tests for cognitive performance. Cognitive evaluation will be repeated 18 months after recruitment. In addition, APOE genotyping will be performed as well.
By obtaining the neuroimaging information, such as severity of white matter change and infarction, cortical and hippocampal atrophy, and SUVRs of [18F]AV-45 and [18F]MNI-958(PMPBB3) PET, the study will be able to investigate the composite influence of cerebrovascular disease and neurodegenerative pathology on the trajectory of cognitive impairment. Group comparisons will be performed using the Chi-square test, independent t test, Mann-Whitney U test, ANOVA test, and multiple linear regression, where appropriate.
Anticipation In this project, we will be able to explore the distribution patterns of amyloid plaque and tau protein among dementia patients with different etiologies, and also evaluate their influence on cognition
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion criteria for VCI (Group A, n=80)
- •Males or females with age >= 20 years old.
- •Patients fulfill the AHA/ASA criteria for vascular cognitive impairment.
- •Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
- •The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
- •Inclusion criteria for AD / MCI (Group B, n=120)
- •Males or females with age >= 20 years old.
- •Patients fulfill the National Institute on Aging (NIA) - Alzheimer's Association Diagnostic Guidelines.
- •Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
- •The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
- •Inclusion criteria for FTD (Group C, n=30)
- •Males or females with age >= 20 years old.
- •Patients fulfill the criteria of probable FTD.
- •Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable).
- •The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
- •Inclusion criteria for normal control (Group D, n=30)
- •Males or females with age >= 20 years old.
- •Provision of signed informed consent.
- •Inclusion criteria for PSP (Group E, n=80)
- •Males or females with age >= 20 years old
- •Patients fulfill the 2017 Movement Disorder Society criteria of PSP.
- •Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable)
- •The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
排除标准
- •Life expectancy less than 1 year.
- •Clinically significant abnormal laboratory values (such as AST/ALT >= 3X of upper normal limits).
- •Clinically significant or unstable medical or psychiatric illness.
- •Epilepsy history.
- •Cognitive impairment resulting from trauma or brain damage.
- •Substance abuse or alcoholism in the past 3 months.
- •Stroke history within the recent 3 months.
研究组 & 干预措施
PMPBB3
- Primary endpoint(s):
A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls. 2. Secondary endpoints:
A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.
干预措施: PMPBB3 (Drug)
PMPBB3
- Primary endpoint(s):
A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls. 2. Secondary endpoints:
A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.
干预措施: AV45 (Drug)
AV45
- Primary endpoint(s):
A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls. 2. Secondary endpoints:
A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.
干预措施: PMPBB3 (Drug)
AV45
- Primary endpoint(s):
A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls. 2. Secondary endpoints:
A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.
干预措施: AV45 (Drug)
结局指标
主要结局
The Clinical Dementia Rating-Sum of Boxes (CDR-SB) change score
时间窗: through study completion, an average of 1.5 year
The Clinical Dementia Rating-Sum of Boxes (CDR-SB) change score between baseline and 18-month follow-up will be calculated for primary endpoint determination. Two-sample independent t-test will be performed to compare the CDR-SB change score between patients positive and negative for tau protein accumulation. Patients will be stratified into tau-positive and tau-negative groups, and the presentations of their cognitive state will be recorded at the 18-month follow-up visit.
Chi-square test will be performed to analyze dementia conversion rate.
时间窗: through study completion, an average of 1.5 year
次要结局
未报告次要终点